Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Brief Summary: This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.


Options:
A: Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab
B: Arm Label: Cohort 2: Participants With Second-line or Beyond Treatments; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Cohort 2: Participants With Second-line or Beyond Treatments
C: Arm Label: Dose Escalation Cohort: Avelumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 20.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, Post-platinum Doublet; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: NSCLC, First Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: Metastatic Breast Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Primary Expansion Cohort: GC/GEJC Non Progressed; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Castrate-resistant Prostate Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Adrenocortical Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Melanoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Mesothelioma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (First Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line); Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Ovarian Cancer; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: Urothelial Carcinoma; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: GC/ GEJC, Third Line; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Arm Label: Efficacy Expansion Cohort: HNSCC; Type: EXPERIMENTAL; Interventions: Drug: Avelumab | Intervention Type: DRUG; Name: Avelumab; Assigned to Arm(s): Dose Escalation Cohort: Avelumab 1.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg, Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly, Dose Escalation Cohort: Avelumab 20.0 mg/kg, Dose Escalation Cohort: Avelumab 3.0 mg/kg, Efficacy Expansion Cohort: GC/ GEJC, Third Line, Efficacy Expansion Cohort: HNSCC, Efficacy Expansion Cohort: Ovarian Cancer, Efficacy Expansion Cohort: Urothelial Carcinoma, Primary Expansion Cohort: GC/GEJC Non Progressed, Primary Expansion Cohort: GC/GEJC Progressed, Primary Expansion Cohort: Metastatic Breast Cancer, Primary Expansion Cohort: NSCLC, First Line, Primary Expansion Cohort: NSCLC, Post-platinum Doublet, Secondary Expansion Cohort: Adrenocortical Carcinoma, Secondary Expansion Cohort: Castrate-resistant Prostate Cancer, Secondary Expansion Cohort: Colorectal Cancer, Secondary Expansion Cohort: Melanoma, Secondary Expansion Cohort: Mesothelioma, Secondary Expansion Cohort: Ovarian Cancer, Secondary Expansion Cohort: Renal Cell Carcinoma (First Line), Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line), Secondary Expansion Cohort: Urothelial Carcinoma
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab

Answer: A